{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T03:56:59Z","timestamp":1788753419010,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011302","name":"Children's Hospital Foundation","doi-asserted-by":"publisher","award":["PCHF9973"],"award-info":[{"award-number":["PCHF9973"]}],"id":[{"id":"10.13039\/100011302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022520","name":"Phoenixville Community Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022938","name":"Children\u2019s Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022938","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010289","name":"Perth Childrens Hospital Foundation","doi-asserted-by":"publisher","award":["9973"],"award-info":[{"award-number":["9973"]}],"id":[{"id":"10.13039\/100010289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Western Pacific"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.lanwpc.2024.101201","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T13:11:14Z","timestamp":1726146674000},"page":"101201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Invasive fungal disease and antifungal prophylaxis in children with acute leukaemia: a multicentre retrospective Australian cohort study"],"prefix":"10.1016","volume":"52","author":[{"given":"Daniel K.","family":"Yeoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Blyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7746-0599","authenticated-orcid":false,"given":"Julia E.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5800-5870","authenticated-orcid":false,"given":"Joanne","family":"Abbotsford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3690-0476","authenticated-orcid":false,"given":"Claudia","family":"Corrente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1836-4075","authenticated-orcid":false,"given":"Rishi S.","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Spelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A.","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin A.","family":"Thursky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0371-8176","authenticated-orcid":false,"given":"Gabrielle M.","family":"Haeusler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl_1","key":"10.1016\/j.lanwpc.2024.101201_bib1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/jpids\/pix046","article-title":"Epidemiology of invasive fungal disease in children","volume":"6","author":"Pana","year":"2017","journal-title":"J\u00a0Pediatric Infect Dis Soc"},{"issue":"3","key":"10.1016\/j.lanwpc.2024.101201_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jpids\/pix030","article-title":"Risk factors for invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review","volume":"7","author":"Fisher","year":"2018","journal-title":"J\u00a0Pediatric Infect Dis Soc"},{"issue":"5","key":"10.1016\/j.lanwpc.2024.101201_bib3","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1128\/AAC.01423-10","article-title":"Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach","volume":"55","author":"Ananda-Rajah","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"12b","key":"10.1016\/j.lanwpc.2024.101201_bib4","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/imj.12595","article-title":"Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014","volume":"44","author":"Fleming","year":"2014","journal-title":"Intern Med J"},{"issue":"3","key":"10.1016\/j.lanwpc.2024.101201_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/pbc.24847","article-title":"Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients","volume":"61","author":"Science","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"10.1016\/j.lanwpc.2024.101201_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27915","article-title":"Invasive fungal infections in children with acute lymphoblastic leukaemia: results from four Australian centres, 2003-2013","volume":"66","author":"Wang","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.lanwpc.2024.101201_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27564","article-title":"Epidemiology of invasive fungal infections in immunocompromised children; an Australian national 10-year review","volume":"66","author":"Bartlett","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"n\/a","key":"10.1016\/j.lanwpc.2024.101201_bib8","article-title":"Invasive fungal disease in children with acute myeloid leukaemia: an Australian multicentre 10-year review","volume":"n\/a","author":"Yeoh","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.lanwpc.2024.101201_bib9","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(20)30723-3","article-title":"8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation","volume":"22","author":"Groll","year":"2021","journal-title":"Lancet Oncol"},{"issue":"27","key":"10.1016\/j.lanwpc.2024.101201_bib10","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.20.00158","article-title":"Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients","volume":"38","author":"Lehrnbecher","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.lanwpc.2024.101201_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/imj.15588","article-title":"Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021","volume":"51","author":"Teh","year":"2021","journal-title":"Intern Med J"},{"issue":"4","key":"10.1016\/j.lanwpc.2024.101201_bib12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. Fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.lanwpc.2024.101201_bib13","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/jama.2019.15702","article-title":"Effect of caspofungin vs fluconazole prophylaxis on invasive fungal disease among children and young adults with acute myeloid leukemia: a randomized clinical trial","volume":"322","author":"Fisher","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.lanwpc.2024.101201_bib14","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/jac\/dkac060","article-title":"Antifungal use in children with acute leukaemia: state of current evidence and directions for future research","volume":"77","author":"Yeoh","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.lanwpc.2024.101201_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212837","article-title":"A\u00a0non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia","volume":"14","author":"Arrieta","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.lanwpc.2024.101201_bib16","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/jac\/dkz481","article-title":"Evaluation of target attainment of oral posaconazole suspension in immunocompromised children","volume":"75","author":"Lai","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.lanwpc.2024.101201_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40262-018-0658-1","article-title":"Clinical pharmacokinetics and dose recommendations for posaconazole in infants and children","volume":"58","author":"Boonsathorn","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.lanwpc.2024.101201_bib18","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/jac\/dkw056","article-title":"Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre","volume":"71","author":"Boast","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.lanwpc.2024.101201_bib19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00520-016-3412-y","article-title":"Critical review of current clinical practice guidelines for antifungal therapy in paediatric haematology and oncology","volume":"25","author":"Morgan","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.lanwpc.2024.101201_bib20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1469-0691.12040","article-title":"ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp","volume":"18","author":"Hope","year":"2012","journal-title":"Clin Microbiol Infection"},{"issue":"681","key":"10.1016\/j.lanwpc.2024.101201_bib21","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3389\/fmicb.2019.00681","article-title":"Incidence and outcome of invasive fungal diseases in children with hematological malignancies and\/or allogeneic hematopoietic stem cell transplantation: results of a prospective multicenter study","volume":"10","author":"Lehrnbecher","year":"2019","journal-title":"Front Microbiol"},{"issue":"3","key":"10.1016\/j.lanwpc.2024.101201_bib22","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/imj.12690","article-title":"Ahead of consensus: a paediatric antifungal prophylaxis census","volume":"45","author":"Osowicki","year":"2015","journal-title":"Intern Med J"},{"issue":"6","key":"10.1016\/j.lanwpc.2024.101201_bib23","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.lanwpc.2024.101201_bib24","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/myc.12960","article-title":"Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology","volume":"62","author":"Cornely","year":"2019","journal-title":"Mycoses"},{"issue":"5","key":"10.1016\/j.lanwpc.2024.101201_bib25","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanwpc.2024.101201_bib26","article-title":"Invasive aspergillosis in adult patients in Australia and New Zealand: 2017-2020","volume":"40","author":"Tio","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"issue":"4","key":"10.1016\/j.lanwpc.2024.101201_bib27","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/myc.12063","article-title":"Invasive fungal infections in paediatric acute myeloid leukaemia","volume":"56","author":"Johnston","year":"2013","journal-title":"Mycoses"},{"issue":"3","key":"10.1016\/j.lanwpc.2024.101201_bib28","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/ejh.12910","article-title":"Retrospective study on the incidence and outcome of proven and probable invasive fungal infections in high-risk pediatric onco-hematological patients","volume":"99","author":"Cesaro","year":"2017","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.lanwpc.2024.101201_bib29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41375-022-01768-x","article-title":"Invasive fungal diseases impact on outcome of childhood ALL\u2014an analysis of the international trial AIEOP-BFM ALL 2009","volume":"37","author":"Lehrnbecher","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.lanwpc.2024.101201_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28035","article-title":"Comment on: invasive fungal infections in children with acute lymphoblastic leukemia","volume":"67","author":"Castagnola","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.lanwpc.2024.101201_bib31","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1097\/MPH.0000000000001022","article-title":"Toxicity of vincristine combined with posaconazole in children with acute lymphoblastic leukemia","volume":"40","author":"Pekpak","year":"2018","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"4","key":"10.1016\/j.lanwpc.2024.101201_bib32","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1439-0507.2011.02158.x","article-title":"Adverse interactions between antifungal azoles and vincristine: review and analysis of cases","volume":"55","author":"Moriyama","year":"2012","journal-title":"Mycoses"},{"issue":"8","key":"10.1016\/j.lanwpc.2024.101201_bib33","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/jac\/dkr223","article-title":"Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia","volume":"66","author":"van Schie","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.lanwpc.2024.101201_bib34","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1128\/AAC.00802-12","article-title":"Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.lanwpc.2024.101201_bib35","doi-asserted-by":"crossref","first-page":"e00010","DOI":"10.1128\/CMR.00010-19","article-title":"Extended dosing regimens for fungal prophylaxis","volume":"32","author":"Lehrnbecher","year":"2019","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"10.1016\/j.lanwpc.2024.101201_bib36","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bjh.16931","article-title":"Benefits of risk-adapted and mould-specific antifungal prophylaxis in childhood leukaemia","volume":"191","author":"Meryk","year":"2020","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.lanwpc.2024.101201_bib37","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/j.1469-0691.2011.03483.x","article-title":"Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients","volume":"17","author":"Bochennek","year":"2011","journal-title":"Clin Microbiol Infection"},{"issue":"8","key":"10.1016\/j.lanwpc.2024.101201_bib38","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/jpids\/piab036","article-title":"Prospective evaluation of galactomannan and (1\u21923) \u03b2-d-Glucan assays as diagnostic tools for invasive fungal disease in children, adolescents, and young adults with acute myeloid leukemia receiving fungal prophylaxis","volume":"10","author":"Fisher","year":"2021","journal-title":"J\u00a0Pediatric Infect Dis Soc"},{"key":"10.1016\/j.lanwpc.2024.101201_bib39","doi-asserted-by":"crossref","DOI":"10.1007\/s11046-023-00714-4","article-title":"The challenge of diagnosing invasive pulmonary aspergillosis in children: a review of existing and emerging tools","author":"Yeoh","year":"2023","journal-title":"Mycopathologia"},{"issue":"10","key":"10.1016\/j.lanwpc.2024.101201_bib40","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/ajh.25585","article-title":"A\u00a0bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: a prospective multicenter study of the SEIFEM group","volume":"94","author":"Marchesi","year":"2019","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.lanwpc.2024.101201_bib41","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1086\/521245","article-title":"The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients","volume":"45","author":"Lass-Fl\u00f6rl","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.lanwpc.2024.101201_bib42","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/pbc.25570","article-title":"Clinical utility of bronchoalveolar lavage and respiratory tract biopsies in diagnosis and management of suspected invasive respiratory fungal infections in children","volume":"62","author":"Batra","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.lanwpc.2024.101201_bib43","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.2014.58.0480","article-title":"Bronchoalveolar lavage and lung biopsy in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic review and meta-analysis","volume":"33","author":"Chellapandian","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.lanwpc.2024.101201_bib44","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1093\/jac\/dkz359","article-title":"Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents","volume":"74","author":"Tragiannidis","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.lanwpc.2024.101201_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106084","article-title":"Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial","author":"Groll","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.lanwpc.2024.101201_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.107058","article-title":"Micafungin twice-a-week for prophylaxis of invasive Aspergillus infections in children with acute lymphoblastic leukaemia: a controlled cohort study","volume":"63","author":"Bury","year":"2024","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"10.1016\/j.lanwpc.2024.101201_bib47","doi-asserted-by":"crossref","first-page":"e00308","DOI":"10.1128\/aac.00308-22","article-title":"Efficacy of cochleated amphotericin B in mouse and human mucocutaneous candidiasis","volume":"66","author":"Desai","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanwpc.2024.101201_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad440","article-title":"Oral lipid nanocrystal amphotericin B for cryptococcal meningitis: a randomized clinical trial","author":"Boulware","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"10370","key":"10.1016\/j.lanwpc.2024.101201_bib49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.lanwpc.2024.101201_bib50","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/QCO.0000000000000611","article-title":"Azole antifungals and new targeted therapies for hematological malignancy","volume":"32","author":"Lindsay","year":"2019","journal-title":"Curr Opin Infect Dis"}],"container-title":["The Lancet Regional Health - Western Pacific"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606524001950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606524001950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:52:31Z","timestamp":1732989151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666606524001950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":50,"alternative-id":["S2666606524001950"],"URL":"https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101201","relation":{},"ISSN":["2666-6065"],"issn-type":[{"value":"2666-6065","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Invasive fungal disease and antifungal prophylaxis in children with acute leukaemia: a multicentre retrospective Australian cohort study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Western Pacific","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101201","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101201"}}